Session 1: 8:30 AM
Private Insurers negotiating drug prices -
Is it necessary in the era of biosimilars?
Health benefits are becoming more difficult for employers to sustain financially. The tools to manage drug costs have included tiered formularies and generic substitution. Most recently biosimilars have been presented as a cost containment opportunity. This presentation will examine the history of product listing agreements with private insurers. The difficulty and potential perils of private insurers joining government product listing agreements. An examination of extent of savings from biosimilars. Finally the current landscape of private insurers negotiating drug prices.
Speaker: Kevin O'Connor, Director, Private & Federal Healthcare, Janssen Inc. (a Johnson & Johnson Company)
Session II: 9:45 AM
Biologics, Biosimilars and the Transition Program
Ned will examine Canada's progress with biosimilar adoption and what public/private payors are doing to support their introduction into the Canadian healthcare environment. He will also discuss why there is such low patient uptake in Canada, and what strategies exist today to increase biosimilar utilization. He will take a look at the increasing body of evidence - both from clinical trials and registries (real-world evidence) - that supports transitioning patients to biosimilars, and he will share what a biosimilar transition program can look like, from both a patient experience and plan sponsor savings perspective.
Speaker: Ned Pojskic, HonBSc, MSc, PhD, Leader, Pharmacy & Health Provider relations, Green Shield Canada
Thursday, April 4, 2019
8:00 – 8:30 am – Registration and Breakfast
8:30 – 9:30 am – Session I
9:45 - 10:45 am - Session II
10:45 - 11:00 am - Q&A
Four Points by Sheraton
210 Preston Parkway
Cambridge, ON N3H 5N1Canada
$50 – SWO or Toronto Chapter Members*
$75 – Non-Member/Guest
$300 – Table of Six
*Chapter members may bring a guest to one educational session at no additional charge. What a great way to introduce a colleague to everything ISCEBS has to offer!
Please click here to register.
Tax ID #25-1503564
Director, Private & Federal Healthcare
Janssen Inc. (a Johnson & Johnson Company)
Kevin O’Connor is the National Director of Federal & Private Healthcare for Janssen Inc. (a Johnson & Johnson Company). Janssen manufacturers and promotes treatments in the areas of biologics, diabetes, HIV, mental health, oncology and women’s health. Kevin has 28 years of experience with Janssen which includes 15 years working with government, private insurers, advisors and brokers.
NED POJSKIC, HonBSc, MSc, PhD
Leader, Pharmacy & Health Provider Relations
Ned Pojskic is Green Shield Canada’s Leader for Pharmacy and Health Provider Relations. In this role, he is responsible for setting GSC’s strategic direction with respect to provider and drug benefits management. He takes the lead in managing stakeholder relations with all health care providers, including pharmacy, dental, and paramedical. Ned is also responsible for overall drug formulary management, including pricing and policy as well as pharmaceutical industry partnerships.
With an industry background that includes a role as Director of Health Policy for the Ontario Pharmacists Association, Ned is a key member of GSC’s Strategic Market Solutions Team. Ned holds Masters and PhD degrees from the Department of Pharmaceutical Sciences at the University of Toronto and is currently appointed as an adjunct professor within the Leslie Dan Faculty of Pharmacy.